RRC ID 64183
著者 Tazawa Y, Usukubo I, Takada K, Takekuma Y, Shibayama Y, Sugawara M.
タイトル Schedule-dependent cytotoxicity of Etoposide and cyclophosphamide in P-glycoprotein-expressing human leukemic K-562 cells.
ジャーナル Biol Pharm Bull
Abstract Combination chemotherapy is often used to treat cancer. Many studies have shown schedule-dependent effects between anticancer drugs. Our previous studies showed that K-562 cells pretreated with non-cytotoxic concentrations of 4-hydroperoxycyclophosphamide (4-HPC), which is a preactivated analog of cyclophosphamide (CY), enhanced the cytotoxicity of etoposide (VP-16). The appearance of cellular resistance to anticancer drugs is a major problem in cancer chemotherapy. P-Glycoprotein (P-gp) plays an important role in drug resistance, and VP-16 is a substrate for this efflux pump. In the present study, we demonstrated schedule-dependent cytotoxicity of VP-16 and CY in P-gp-overexpressed K-562/P-gp cells. Cytotoxicity of VP-16 was enhanced in K-562/P-gp cells that were pretreated with a non-cytotoxic concentration of 4-HPC compared to that of cells not treated with 4-HPC. 4-HPC arrested the cell cycle at S phase. Cells in S phase are most sensitive to VP-16. The results suggest that cell cycle arrest by 4-HPC pretreatment may be responsible for the enhanced cytotoxicity of VP-16. The findings in this study should lead to improvements in clinical combination chemotherapy.
巻・号 37(8)
ページ 1323-9
公開日 2014-1-1
DOI 10.1248/bpb.b14-00207
PII DN/JST.JSTAGE/bpb/b14-00207
PMID 25087953
MeSH ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism* Antineoplastic Agents / administration & dosage* Biological Transport / drug effects Cell Cycle / drug effects Cell Survival / drug effects Cyclophosphamide / administration & dosage Cyclophosphamide / analogs & derivatives* Drug Administration Schedule Etoposide / administration & dosage* Humans K562 Cells Leukemia / drug therapy Leukemia / metabolism
IF 1.863
リソース情報
ヒト・動物細胞 K-562(RCB1635)